Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.’ The study aims to assess the safety and efficacy of PF-06939926, a gene therapy, in boys with Duchenne Muscular Dystrophy (DMD). This research is significant as it explores a potential treatment for a severe genetic disorder that affects muscle function.
The intervention being tested is PF-06939926, a genetic therapy administered via intravenous infusion. Its purpose is to improve muscle function in DMD patients by increasing dystrophin expression.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Participants are randomly assigned to receive either the gene therapy or a placebo, with masking applied to participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment-focused.
The study began on November 5, 2020, with primary completion expected in May 2025 and estimated study completion in July 2025. The latest update was submitted in July 2025, indicating ongoing data collection and analysis.
This study could significantly impact Pfizer’s market position, potentially boosting investor confidence if successful results are reported. The competitive landscape includes other companies exploring gene therapies for DMD, which could influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.